
Global demand for Pfizer Inc's (NYSE:PFE) Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions, a Reuters review of data and interviews with experts has found.
Amid a recent rise in COVID-19 infections, Paxlovid supply far outstripped demand in the U.S., the U.K., Japan, and South Korea, data from health ministries and Reuters interviews with doctors and pharmacists found.